Types of lymphoma and method for prognosis thereof

• US 20050282177A1
• Filed: 09/22/2004
• Published: 12/22/2005
• Est. Priority Date: 09/22/2003
• Status: Abandoned Application

• Current Assignee: Aichi Prefecture, NGK Insulators Limited
• Original Assignee: Aichi Prefecture, NGK Insulators Limited
• Inventors: Yoshida, Yasuko, Seto, Masao, Kira, Shigeki, Tagawa, Hiroyuki
• Application Number:
  US10/946,068
• Publication Number:
  US 20050282177A1
• Time in Patent Office: Days
• US Class Current: 435/6.14
• CPC Class Codes: C12Q 1/6881 for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/118 Prognosis of disease development
• CPC Class Codes: C12Q 2600/178 miRNA, siRNA or ncRNA

Abstract

A method for determining the prognosis of a CD5+DLBCL patient and a CD5−DLBCL patient is provided. It is determined that, in the chromosomal DNA from a patient with lymphoma, (1) the prognosis of the CD5+DLBCL patient with amplification of 13q21.1-q31.3 region is poor; (2) the prognosis of the CD5+DLBCL patient with deletion of 1p36.21-p36.13 region is poor; and (3) the prognosis of the CD5−DLBCL patient with amplification of 5p15.33-p14.2 region is good.

Claims

1. A method for determining the prognosis of a patient with CD5−

positive diffuse large B-cell lymphoma (CD5+DLBCL) and a patient with CD5−

negative diffuse large B-cell lymphoma (CD5−

DLBCL), which comprises isolating a chromosomal DNA from the respective patients with lymphoma, and determining that, in the chromosomal DNA,

(1) the prognosis of the CD5+DLBCL patient with amplification of chromosome 13 q21.1-q31.3 (13q21.1-q31.3) region is poor;

(2) the prognosis of the CD5+DLBCL patient with deletion of chromosome 1 p36.21-p36.13 (1p36.21-p36.13) region is poor; and

(3) the prognosis of the CD5−

DLBCL patient with amplification of chromosome 5 p15.33-p14.2 (5 p15.33-p14.2) region is good.

2. The method according to claim 1, wherein the amplification or the deletion of the chromosomal region is measured by hybridization of a plurality of DNA probes containing the chromosomal region with a chromosomal DNA from the patient.

3. The method according to claim 2, wherein the DNA probes are BAC/PAC DNA clones.

4. The method according to claim 2 or 3, wherein the hybridization is carried out on a solid phase carrier.

5. A DNA array used for the method according to claim 4, in which the plurality of DNA probes containing the chromosomal region are immobilized on the solid phase carrier.

6. The DNA array of claim 5, wherein the DNA probes are BAC/PAC DNA clones.

7. A method for determining the prognosis of a CDS+DLBCL patient and a CD5−

DLBCL patient, which comprises isolating a biological sample from the patient with lymphoma, and determining that, in the biological sample,

(1) the prognosis of the CD5+DLBCL patient with an increased gene expression in 13q21.1-q31.3 region is poor;

(2) the prognosis of the CD5+DLBCL patient with a decreased gene expression in 1p36.21-p36.13 region is poor; and

(3) the prognosis of the CD5−

DLBCL patient with an increased gene expression in 5p15.33-p14.2 region is good.

8. The method according to claim 7, wherein the gene in 13q21.1-q31.3 region is C13 or f25 gene having the following characteristics of:

(a) encoding a protein containing the amino acid sequences of SEQ ID NO;

4 and SEQ ID NO;

5; and

/or

(b) transcribing the following precursor micro RNAs;

miR91-precursor-13 micro RNA, miR18-precursor-1, 3 micro RNA miR19a-precursor-13 micro RNA, miR19b-precursor-13 micro RNA and miR92-precursor-13 micro RNA, and the following mature micro RNAs;

miR-17, miR-91, miR-18, miR-19a, miR-20, miR-19b and miR-92.

9. The method according to claim 7, wherein the increased gene expression or the decreased gene expression is etermined by measuring a gene transcript.

10. The method according to claim 9, wherein the gene transcript is a mRNA.

11. The method according to claim 10, wherein the increased gene expression or the decreased gene expression is measured by hybridization of a DNA probe which is a full length or a part of the gene with a gene mRNA or cDNA.

12. The method according to claim 11, wherein the hybridization is carried out on a solid phase carrier.

13. A DNA array used for the method according to claim 12, in which the DNA probes are immobilized on the solid phase carrier.

14. The method according to claim 9, wherein the gene transcript is a protein.

15. The method according to claim 14, wherein the increase or decrease of the gene transcript is determined by using an antibody which specifically binds to the protein.

16. An antibody used for the method according to claim 15.

17. The antibody of claim 16, which recognizes the amino acid sequences of SEQ ID NO:

4 and SEQ ID NO;

5.

18. A purified polynucleotide of C13 or f25 gene, which has the following characteristics of:

(a) encoding a protein containing the amino acid sequences of SEQ ID NO;

4 and SEQ ID NO;

5; and

/or

(b) transcribing the following precursor micro RNAs;

miR91-precursor-13 micro RNA, miR18-precursor-1, 3 micro RNA, miR19a-precursor-13 micro RNA, miR19b-precursor-13 micro RNA and miR92-precursor-13 micro RNA, and the following mature micro RNAs;

miR-17, miR-91, miR-18, miR-19a, miR-20, miR-19b and miR-92.

19. An oligonucleotide probe which comprises a partial continuous sequence of the polynucleotide of claim 18 and is hybridized to C13 or f25 gene under a stringent condition.

20. A DNA array, which comprises the oligonucleotide probe of claim 19.

21. An oligonucleotide primer for PCR amplification of C13 or f25 gene.